Biomarkers for prostate cancer
View abstract on PubMed
Summary
This summary is machine-generated.Prostate cancer biomarkers like prostate-specific antigen (PSA) aid screening and detection. Further research is needed to validate existing markers and discover new ones for aggressive prostate cancer identification.
Area Of Science
- Urology
- Oncology
- Biomarker Discovery
Background
- Prostate cancer management has been significantly advanced by the development of effective biomarkers.
- Prostate-specific antigen (PSA) is a widely used but non-specific biomarker for prostate cancer detection.
Purpose Of The Study
- To review the current literature on prostate cancer biomarkers.
- To highlight the utility of various serum, tissue, and urine biomarkers in prostate cancer management.
- To identify future research directions for improved prostate cancer diagnostics.
Main Methods
- Comprehensive literature review of prostate cancer biomarkers.
- Categorization of biomarkers into serum, tissue, and urine markers.
- Analysis of existing and emerging prostate cancer detection and prognostication tools.
Main Results
- Identified key serum markers: PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2.
- Highlighted important tissue markers: AMACR, methylated GSTP1, and TMPRSS2-ETS gene rearrangement.
- Included a significant urine marker: DD3PCA3/UPM-3.
Conclusions
- Existing prostate cancer biomarkers have revolutionized disease management.
- Validation of current biomarkers is crucial for clinical application.
- Discovery of novel biomarkers is essential for identifying aggressive prostate cancer cases.